**Technology Advisory Committee B**

**Topic [ID1598] Encorafenib in dual or triple therapy for previously treated BRAF V600E mutation-positive metastatic colorectal cancer**

**Publication Date: 06/01/2021**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Name | Role with NICE | Type of interest | Description of interest | Interestarose | Interestdeclared | Interest ceased | Comments |
| Dr Naureen Starling | Clinical expert | Direct- Financial | Has received support to attend advisory boards and received honoraria from comparator companies. | N/A | 04/05/2020 | N/A | It was agreed that this declaration would not prevent her from participating in this section of the meeting. |
| Dr Hapreet Wasan | Clinical expert | Direct- Financial | Has attended advisory boards for Pierre Fabre and has done education development work on BRAFV600E in colorectal cancer and the BEACON data | N/A | 13/03/2020 | N/A | It was agreed that this declaration would not prevent him from participating in this section of the meeting. |
| Dr Hapreet Wasan | Clinical expert | Direct- Non-financial | He is the UK chief investigator of the BEACON study.  | N/A | 13/03/2020 | N/A | It was agreed that this declaration would not prevent him from participating in this section of the meeting. |
| Mr Mike Chambers | TAC B Committee member | Direct- Financial | Has been involved in running a training programme for Roche, who manufacture a potential comparator therapy. This did not involve the consideration of any Roche products | N/A | 18/08/2020 | N/A | It was agreed that this declaration would not prevent him from participating in this section of the meeting. |
| Dr Nick Latimer | TAC B Committee member | Direct- Financial | Has provided advice to Pierre Fabre regarding the encorafenib trial  | N/A | 20/07/2020 | N/A | Due to this declaration, he withdrew from attending the meeting |